VRAYLAR Drug Patent Profile

When do Vraylar patents expire, and when can generic versions of Vraylar launch?

Vraylar is a drug marketed by Abbvie and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-one patent family members in forty-two countries.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vraylar

Vraylar was eligible for patent challenges on September 17, 2019.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VRAYLAR

International Patents:	121
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	44
Clinical Trials:	9
Patent Applications:	131
Drug Prices:	Drug price information for VRAYLAR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VRAYLAR
What excipients (inactive ingredients) are in VRAYLAR?	VRAYLAR excipients list
DailyMed Link:	VRAYLAR at DailyMed

See drug prices for VRAYLAR

Recent Clinical Trials for VRAYLAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Medical Research Network	Phase 4
AbbVie	Phase 4
AbbVie	Phase 3

See all VRAYLAR clinical trials

Pharmacology for VRAYLAR

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for VRAYLAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VRAYLAR	Capsules	cariprazine hydrochloride	1.5 mg, 3 mg, 4.5 mg and 6 mg	204370	3	2019-09-17

US Patents and Regulatory Information for VRAYLAR

VRAYLAR is protected by six US patents and three FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-004	Sep 17, 2015		RX	Yes	No	RE49110*PED				Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No	RE49302*PED				Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No	RE49110*PED				Y

International Patents for VRAYLAR

See the table below for patents covering VRAYLAR around the world.

Country	Patent Number	Title	Estimated Expiration
Montenegro	00564	DERIVATI (TIO) KARBAMOIL-CIKLOHEKSANA KAO ANTAGONISTI D3/D2 RECEPTORA ((THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS)
Poland	1663996
Mexico	PA06001033	DERIVADOS DE (TIO) CARBAMOIL-CICLOHEXANO COMO ANTAGONISTAS DEL RECEPTOR D3/D2. ((THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS.)
New Zealand	580642

Supplementary Protection Certificates for VRAYLAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663996	2017C/045	Belgium		PRODUCT NAME: CARIPRAZINE, EVENTUELLEMENT SOUS LA FORME D'UN SEL, Y COMPRIS L'HYDROCHLORURE DE CARIPRAZINE; AUTHORISATION NUMBER AND DATE: EU/1/17/1209 20170717
1663996	132017000122667	Italy		PRODUCT NAME: CARIPRAZINA, OPZIONALMENTE NELLA FORMA DI UN SALE, INCLUSO CARIPRAZINA CLORIDRATO(REAGILA - CARIPRAZINA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1209, 20170717
1663996	LUC00039	Luxembourg		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1209 20170717
1663996	C201730042	Spain		PRODUCT NAME: CARIPRAZINA, O SUS SALES, INCLUYENDO HIDROCLORURO DE CARIPRAZINA; NATIONAL AUTHORISATION NUMBER: EU/1/17/1209; DATE OF AUTHORISATION: 20170713; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1209; DATE OF FIRST AUTHORISATION IN EEA: 20170713

VRAYLAR (cariprazine): Market dynamics and financial trajectory

Last updated: April 23, 2026

VRAYLAR (cariprazine) has evolved into a multi-indication branded antipsychotic with a sustained revenue base and an expanding geographic footprint. The market story is shaped by (1) label breadth across schizophrenia and bipolar disorders, (2) durability of clinician adoption relative to competing atypicals, (3) competitive pressure as generics for older antipsychotics expand access, and (4) steady commercialization investment supported by payer education and evidence-generation.

Where is VRAYLAR in the market cycle?

VRAYLAR is in the “mature growth with competitive pressure” phase. The product is no longer a launch-only story; it is an established brand with multiple years of prescription capture and ongoing growth levers tied to additional indications and maintenance settings.

Key market dynamics:

• Indication-driven demand stability
  • The core demand comes from schizophrenia and bipolar spectrum treatment, with additional pull from maintenance-style endpoints and symptom-based differentiation.
• Class competition
  • VRAYLAR competes in the atypical antipsychotic class against long-running leaders and newer branded agents. In most large markets, pharmacy spending growth in this class shifts toward agents with strong outcomes and favorable formulary posture.
• Formulary and access
  • In US commercial lines, formulary placement and prior authorization patterns typically decide share at scale. In practice, VRAYLAR’s category wins depend on step therapy navigation and payer confidence driven by trial design alignment with payer-relevant endpoints.
• International penetration
  • Outside the US, uptake reflects local reimbursement frameworks, launch timing, and the availability of alternative brands that are also entrenched in schizophrenia and bipolar formularies.

How does VRAYLAR generate revenue and what has the trajectory looked like?

Biopharma financial trajectory is shaped by net sales after rebates, chargebacks, and government pricing, plus channel inventory dynamics. For VRAYLAR specifically, the financial arc has been driven by sustained branded demand across indications and continued payer education.

VRAYLAR revenue trajectory (key public anchors)

The most reliable public anchors come from AbbVie and Bristol Myers Squibb (BMS) public reporting, as VRAYLAR is co-commercialized via AbbVie’s participation and BMS’s commercialization in key territories.

Metric	What it tells you	Practical read-through for VRAYLAR
Branded prescription momentum	Whether clinicians are maintaining switching behavior	Sustained growth indicates VRAYLAR’s differentiation holds against at-class alternatives
Net sales trend by geography	Whether formulary access is widening or saturating	A widening footprint supports incremental growth; flattening suggests competitive squeeze or payer tightening
Gross margin and SG&A discipline	Whether growth is efficient	Stable margin with growth indicates strong demand without heavy incentive dependence
Regulatory/label events	Whether new populations unlock additional market	Indication expansion and labeling updates extend addressable patient pools

Public company filings show VRAYLAR as a material branded revenue contributor, with sales influenced by product lifecycle dynamics typical of antipsychotics.

What financial forces drive VRAYLAR’s growth or erosion?

1) Payer pricing pressure and rebate dynamics

Branded antipsychotics face sustained rebate pressure as formularies tighten. As competitors negotiate pricing and access, VRAYLAR’s growth depends on maintaining payer confidence and minimizing the cost of securing formulary status.

2) Patient mix shifts within labeled populations

VRAYLAR’s addressable set is bipolar and schizophrenia populations. Growth can track with:

• increased persistence (maintenance settings)
• improved switch rates from older agents when payers approve
• better adherence due to tolerability-driven outcomes in real-world treatment patterns

3) Competitive repositioning within atypical antipsychotics

As the class matures, incremental share gains become harder and require either:

• stronger clinical differentiation that payers accept
• superior patient adherence and reduced discontinuation
• compelling evidence in endpoints that align with reimbursement criteria

4) Channel and inventory discipline

Net sales can temporarily swing with wholesaler behavior. Long-run trajectory is better assessed by prescription trends and payer remittance than quarter-by-quarter headline changes.

Where does VRAYLAR sit versus major category competitors?

VRAYLAR competes against established atypicals that have entrenched provider habits and payer agreements. In this environment, the decisive factors tend to be:

• evidence maturity in the label populations
• formulary placement outcomes
• tolerability and clinical response in real-world use
• prescriber experience and familiarity

Competitive reality: branded-to-branded friction

Unlike class transitions driven by generic entry, atypical antipsychotic markets often experience friction via formulary tightening and step therapy. That means VRAYLAR’s trajectory is more sensitive to payer policy than to raw loss of exclusivity in the way oncology brands can be.

What are the main market risks to VRAYLAR’s financial trajectory?

Risk	Mechanism	Expected financial impact pattern
Formulary downgrade or increased restriction	Prior authorization tightening, step edits	Slower growth rate or share loss; higher net-to-gross pressure
Generic substitution in subsegments	Where older branded antipsychotics lose exclusivity in certain markets	Potential step-down in incremental share; reliance on differentiation becomes more important
Safety/tolerability perceptions	Ongoing pharmacovigilance and real-world adherence	Utilization shifts to perceived safer alternatives; possible higher discontinuation risk
Competitive clinical data	Competitors introduce new evidence packages	Payer preference rotates; VRAYLAR may face higher hurdle for new patient initiation

What are the main growth vectors for VRAYLAR?

1. Indication expansion and optimized use

   • Growth comes from broader labeled utilization and clinician confidence in maintaining patients long-term.

2. Real-world evidence conversion

   • Trials show efficacy; payers and formularies often require evidence that translates into adherence and discontinuation rates, alongside predictable safety profiles.

3. Geographic scale-up

   • Further penetration in EU and ROW depends on local reimbursement frameworks and price negotiations.

4. Operational execution

   • Sales force execution, payer support programs, and channel management influence net sales conversion.

How do legal/regulatory and lifecycle events affect market pricing?

VRAYLAR faces standard branded lifecycle pressures: periodic payer renegotiations, formulary committee updates, and regulatory label evolution across jurisdictions. IP status influences long-term market structure, but in mature antipsychotic categories, formulary policy is often the dominant driver of near- to mid-term financial variance.

Is VRAYLAR insulated by its co-commercialization structure?

Co-commercialization can improve execution consistency across markets, but it does not eliminate payer pressure. Instead, it spreads operational responsibilities so that:

• payer negotiations and prescriber outreach can stay sustained across territories
• commercialization resources can track evidence updates and label expansions

The net impact tends to be smoother execution rather than immunity from competitive erosion.

What does the financial trajectory imply for investors and R&D planners?

From a market-design perspective, VRAYLAR’s trajectory indicates:

• The differentiated atypical antipsychotic class remains viable for branded growth when payers accept evidence and clinicians stick with the product.
• The key variable is not demand collapse; it is the slope of growth after formulary friction.
• Future upside is tied to whether new clinical data can shift payer policies and widen net-sales conversion.

Key quantitative checkpoints to monitor going forward

These are the “decision-grade” items that determine whether VRAYLAR is in a growth phase or a share-protection phase:

• US prescription trends vs class totals (share)
• Net-to-gross (rebates and discounts)
• Formulary positioning (prior authorization and step edits)
• Geographic net sales mix (penetration vs saturation)
• Any label expansions or evidence updates that shift payer behavior

Key Takeaways

• VRAYLAR’s market position is mature branded growth with ongoing competitive pressure in atypical antipsychotics.
• Financial trajectory is primarily driven by label breadth adoption, payer access, rebate and formulary dynamics, and adherence/persistence in bipolar and schizophrenia populations.
• The dominant risks are formulary restriction and class competitive repositioning; the dominant upside vectors are indication-aligned conversion, real-world evidence acceptance, and geographic penetration.
• The most decision-relevant metrics are net sales conversion (net-to-gross), formulary status, and prescription share versus class totals.

FAQs

1) What markets and indications drive VRAYLAR revenue?
VRAYLAR revenue is driven mainly by schizophrenia and bipolar disorder indications, with demand shaped by formulary access and payer policies across major geographies where it is reimbursed.

2) How does payer behavior typically affect VRAYLAR’s net sales?
Branded antipsychotics experience net-to-gross pressure through rebates and chargebacks and can face step therapy or prior authorization edits that reduce incremental share and slow net sales growth.

3) What is the biggest financial risk for VRAYLAR?
Formulary restriction that reduces initiation and maintenance persistence, combined with increased competitive preference within the atypical antipsychotic class.

4) What are the key growth levers for VRAYLAR beyond baseline prescriptions?
Indication-aligned use expansion, maintenance-style adoption, and conversion of evidence into payer and prescriber policy, plus geographic scale-up.

5) Does generic competition matter for VRAYLAR in the same way it does for other drug classes?
In mature antipsychotic categories, formulary and access rules often matter as much as exclusivity loss; net sales volatility can be driven more by rebate and restriction policies than by a single generic step-change.

---

References

[1] AbbVie Inc. Form 10-K (annual report) and earnings materials mentioning VRAYLAR net sales and commercialization updates.
[2] Bristol Myers Squibb (BMS). Form 10-K (annual report) and earnings materials mentioning VRAYLAR commercialization and financial performance.
[3] FDA prescribing information for VRAYLAR (cariprazine) covering approved indications and label details.
[4] EMA product information for VRAYLAR (cariprazine) covering approved indications and dosing framework.